ThermoFisher News & Analysis
2 articles
Market Mood
Arcturus Therapeutics (ARCT) Gains 5.8% on Thermo Fisher Deal
Arcturus Therapeutics (ARCT) experienced a 5.8% increase following an agreement with Thermo Fisher. This deal signifies a strategic collaboration that could enhance Arcturus' operational capabilities and market positioning. The market reacted positively, indicating investor confidence in the partnership's potential benefits. Overall, this development may influence Arcturus' future stock performance as it leverages the resources provided through this collaboration.
Read More: Arcturus Therapeutics (ARCT) Gains 5.8% on Thermo Fisher Deal
Thermo Fisher Completes $8.875 Billion Acquisition of Clario Holdings
On March 24, 2026, Thermo Fisher Scientific Inc. announced the completion of its acquisition of Clario Holdings, Inc. for $8.875 billion in cash, with additional performance-dependent earnouts. The Clario business will enhance Thermo Fisher's Laboratory Products and Biopharma Services segment. It is projected to contribute $0.45 to adjusted EPS in its first year and generate approximately $175 million in adjusted operating income from synergies by year five. This acquisition is expected to drive high single-digit growth in Clario’s business and improve operating margins for Thermo Fisher.
Read More: Thermo Fisher Completes $8.875 Billion Acquisition of Clario Holdings